Lymphoma, Follicular

Oncology
9
Pipeline Programs
7
Companies
9
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
4
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
467%
Small Molecule
117%
ADC
117%
+ 4 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Celltrion
CelltrionKorea - Incheon
1 program
1
RituxanPhase 31 trial
Active Trials
NCT02162771Completed140Est. Dec 2018
UP
UCB PharmaBelgium - Brussels
1 program
1
inotuzumab ozogamicinPhase 3ADC
GSK
GSKLONDON, United Kingdom
4 programs
1
1
2
OfatumumabPhase 2Monoclonal Antibody1 trial
OfatumumabPhase 2Monoclonal Antibody1 trial
HuMax-CD20Phase 1/21 trial
Follicular LymphomaPhase 11 trial
Active Trials
NCT00315731Completed15Est. Jun 2013
NCT00092274Withdrawn0Est. Jan 2005
NCT00394836Completed116Est. Sep 2013
+1 more trials
Genentech
GenentechCA - Oceanside
1 program
1
MosunetuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05410418Active Not Recruiting34Est. Apr 2029
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
MosunetuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05849857Recruiting80Est. Aug 2028
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 695500Phase 11 trial
Active Trials
NCT01950273Completed95Est. Dec 2015
E
EisaiChina - Liaoning
1 program
TazemetostatN/ASmall Molecule1 trial
Active Trials
NCT05228158Active Not Recruiting145Est. Mar 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
CelltrionRituxan
RocheMosunetuzumab
GenentechMosunetuzumab
GSKOfatumumab
GSKOfatumumab
GSKHuMax-CD20
Boehringer IngelheimBI 695500
GSKFollicular Lymphoma
EisaiTazemetostat

Clinical Trials (9)

Total enrollment: 684 patients across 9 trials

NCT02162771CelltrionRituxan

To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan

Start: Jul 2014Est. completion: Dec 2018140 patients
Phase 3Completed
NCT05849857RocheMosunetuzumab

Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries

Start: Sep 2023Est. completion: Aug 202880 patients
Phase 2Recruiting
NCT05410418GenentechMosunetuzumab

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Start: Oct 2022Est. completion: Apr 202934 patients
Phase 2Active Not Recruiting
NCT00494780GSKOfatumumab

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

Start: Jun 2007Est. completion: Sep 201059 patients
Phase 2Completed
NCT00394836GSKOfatumumab

HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

Start: May 2007Est. completion: Sep 2013116 patients
Phase 2Completed
NCT00092274GSKHuMax-CD20

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Start: Sep 2004Est. completion: Jan 20050
Phase 1/2Withdrawn
NCT01950273Boehringer IngelheimBI 695500

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

Start: Sep 2013Est. completion: Dec 201595 patients
Phase 1Completed
NCT00315731GSKFollicular Lymphoma

A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma

Start: Mar 2003Est. completion: Jun 201315 patients
Phase 1Completed
NCT05228158EisaiTazemetostat

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

Start: Aug 2021Est. completion: Mar 2028145 patients
N/AActive Not Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4h ago

Office Administrator

SystImmune
4h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
4h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
4h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 684 patients
7 companies competing in this space

Related Indications

Breast Cancer(577)Prostate Cancer(385)Non-small Cell Lung Cancer(378)Multiple Myeloma(359)Cancer(249)Advanced Solid Tumors(226)Acute Myeloid Leukemia(209)Neoplasms(199)Colorectal Cancer(171)Melanoma(170)